DK0739898T3 - Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf - Google Patents

Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf

Info

Publication number
DK0739898T3
DK0739898T3 DK96103533T DK96103533T DK0739898T3 DK 0739898 T3 DK0739898 T3 DK 0739898T3 DK 96103533 T DK96103533 T DK 96103533T DK 96103533 T DK96103533 T DK 96103533T DK 0739898 T3 DK0739898 T3 DK 0739898T3
Authority
DK
Denmark
Prior art keywords
monosternucleic
phosphonone
acids
preparation
phosphonone monosternucleic
Prior art date
Application number
DK96103533T
Other languages
English (en)
Inventor
Peyman Dr Anuschirwan
Gerhard Dr Breipohl
Eugen Dr Uhlmann
Holger Dr Wallmeier
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19508923A external-priority patent/DE19508923A1/de
Priority claimed from DE1995143865 external-priority patent/DE19543865A1/de
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Application granted granted Critical
Publication of DK0739898T3 publication Critical patent/DK0739898T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4071—Esters thereof the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4087—Esters with arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)
DK96103533T 1995-03-13 1996-03-07 Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf DK0739898T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19508923A DE19508923A1 (de) 1995-03-13 1995-03-13 Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung
DE1995143865 DE19543865A1 (de) 1995-11-24 1995-11-24 Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung

Publications (1)

Publication Number Publication Date
DK0739898T3 true DK0739898T3 (da) 2001-12-10

Family

ID=26013308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96103533T DK0739898T3 (da) 1995-03-13 1996-03-07 Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf

Country Status (22)

Country Link
US (2) US5874553A (da)
EP (1) EP0739898B1 (da)
JP (1) JP3917680B2 (da)
KR (1) KR100434213B1 (da)
CN (1) CN1060781C (da)
AR (1) AR002714A1 (da)
AT (1) ATE206131T1 (da)
AU (1) AU706470B2 (da)
BR (1) BR9600993B1 (da)
CA (1) CA2171589C (da)
CZ (1) CZ292037B6 (da)
DE (1) DE59607750D1 (da)
DK (1) DK0739898T3 (da)
ES (1) ES2165446T3 (da)
HK (1) HK1012398A1 (da)
HU (1) HUP9600647A3 (da)
IL (1) IL117423A (da)
NO (1) NO328646B1 (da)
NZ (1) NZ286150A (da)
PL (1) PL184920B1 (da)
PT (1) PT739898E (da)
UA (1) UA44253C2 (da)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7812149B2 (en) * 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050053976A1 (en) * 1996-06-06 2005-03-10 Baker Brenda F. Chimeric oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
WO2005121368A1 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Chimeric gapped oligomeric compositions
US20040147022A1 (en) * 1996-06-06 2004-07-29 Baker Brenda F. 2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US20040203024A1 (en) * 1996-06-06 2004-10-14 Baker Brenda F. Modified oligonucleotides for use in RNA interference
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
EP1088585A3 (de) * 1997-02-17 2004-09-15 Gesellschaft für biotechnologische Forschung mbH (GBF) Automatisiertes simultanes chemisches Syntheseverfahren
IL132518A (en) * 1997-05-14 2007-05-15 Morphochem Ag Isonitrile derivatives and processes for the preparation thereof
DE19741715A1 (de) 1997-09-22 1999-03-25 Hoechst Ag Pentopyranosyl-Nucleosid, seine Herstellung und Verwendung
DE19741738A1 (de) * 1997-09-22 1999-03-25 Hoechst Ag Linker-Nucleosid, seine Herstellung und Verwendung
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
GB9929487D0 (en) * 1999-12-15 2000-02-09 Zeneca Ltd Antisense oligonucleotides
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
US20040014644A1 (en) * 2000-03-14 2004-01-22 Vladimir Efimov Oligonucleotide analogues and methods of use for modulating gene expression
EP1263773A4 (en) 2000-03-14 2005-08-31 Active Motif OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF IMPLEMENTATION
DE10019135A1 (de) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
DE10019136A1 (de) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung
EP1560839A4 (en) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc CHIMERIC OLIGOMER COMPOUNDS AND THEIR USE IN GENE MODULATION
WO2004044136A2 (en) * 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2’-modified nucleosides for use in gene modulation
US9150605B2 (en) 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US7276599B2 (en) * 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
AU2004253455B2 (en) 2003-06-03 2011-03-03 Eli Lilly And Company Modulation of survivin expression
EP1636342A4 (en) * 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMERIC COMPOUNDS FOR GENE MODULATION
US7683036B2 (en) 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
AU2004274021B2 (en) 2003-09-18 2009-08-13 Isis Pharmaceuticals, Inc. 4'-thionucleosides and oligomeric compounds
US8569474B2 (en) * 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP2700720A3 (en) 2004-03-15 2015-01-28 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of RNA by RNASE H
US8394947B2 (en) * 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
WO2005121372A2 (en) * 2004-06-03 2005-12-22 Isis Pharmaceuticals, Inc. Double strand compositions comprising differentially modified strands for use in gene modulation
US7884086B2 (en) * 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US20060281100A1 (en) * 2005-06-14 2006-12-14 Shen Gene G Thiotriphosphate nucleotide dye terminators
CN102264357B (zh) * 2008-12-22 2015-04-01 宝丽化成工业有限公司 黑色素产生抑制剂
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
KR20220145813A (ko) * 2019-11-20 2022-10-31 유니버셜 시퀀싱 테크놀로지 코퍼레이션 분자 일렉트로닉스를 위한 조작된 dna

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350704A (en) * 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4374847A (en) * 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
US5264562A (en) * 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
DE4016596A1 (de) * 1990-05-23 1991-11-28 Hoechst Ag Ein neues kupplungsreagenz fuer die peptidsynthese
KR930016437A (ko) * 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
DK0691968T3 (da) * 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
WO1994022891A1 (en) * 1993-03-31 1994-10-13 Sterling Winthrop Inc. Oligonucleotides with amide linkages replacing phosphodiester linkages
EP0691971A1 (en) * 1993-04-01 1996-01-17 University Of Virginia 7-azabicyclo- 2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents
DE4321946A1 (de) * 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
HK1012398A1 (en) 1999-07-30
KR960034213A (ko) 1996-10-22
KR100434213B1 (ko) 2004-09-10
UA44253C2 (uk) 2002-02-15
JP3917680B2 (ja) 2007-05-23
ATE206131T1 (de) 2001-10-15
NZ286150A (en) 1998-07-28
DE59607750D1 (de) 2001-10-31
EP0739898A2 (de) 1996-10-30
PL313207A1 (en) 1996-09-16
HUP9600647A1 (en) 1997-05-28
CN1060781C (zh) 2001-01-17
EP0739898B1 (de) 2001-09-26
CN1138588A (zh) 1996-12-25
JPH08259579A (ja) 1996-10-08
PT739898E (pt) 2002-03-28
IL117423A0 (en) 1996-07-23
NO961006L (no) 1996-09-16
IL117423A (en) 2006-08-20
CZ74396A3 (en) 1996-10-16
AU706470B2 (en) 1999-06-17
US5874553A (en) 1999-02-23
HUP9600647A3 (en) 1998-04-28
CZ292037B6 (cs) 2003-07-16
EP0739898A3 (de) 1998-09-16
AU4802896A (en) 1996-09-26
HU9600647D0 (en) 1996-05-28
CA2171589A1 (en) 1996-09-14
ES2165446T3 (es) 2002-03-16
AR002714A1 (es) 1998-04-29
PL184920B1 (pl) 2003-01-31
US6127346A (en) 2000-10-03
BR9600993A (pt) 1997-12-30
NO328646B1 (no) 2010-04-19
CA2171589C (en) 2011-05-10
BR9600993B1 (pt) 2010-05-18
NO961006D0 (no) 1996-03-12

Similar Documents

Publication Publication Date Title
DK0739898T3 (da) Phosphononmoneosternukleinsyrer, fremgangsmåde til fremstilling deraf og anvendelse deraf
NO960772D0 (no) Naftylforbindelser og fremgangsmåte for fremstilling derav, mellomprodukter og preparater
NO973836L (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
DK0850948T3 (da) Propiophenonderivater og fremgangsmåde til fremstilling deraf
DK0826673T3 (da) Acetamidderivater, fremgangsmåde til fremstilling deraf og medicinske præparater
DK0906029T3 (da) Isoflavonberiget sojaproteinprodukt og fremgangsmåde til fremstilling heraf
NO20012158D0 (no) Substituerte 2-fenylbenzimidazoler, fremgangsmåte til fremstilling og anvendelse derav
DK0828840T3 (da) Alkalisk cellulase og fremgangsmåde til fremstilling deraf
DK0729956T3 (da) Benzothi9phenforbindelser, emllemprodukter, præparater og fremgangsmåder
DK0863856T3 (da) Komposteringssystem og fremgangsmåde
NO973263L (no) Fremgangsmåte for fremstilling og anvendelse av vandige emulsjoner
DK0773984T3 (da) Enzymholdig granuleret substans og fremgangsmåde til fremstilling heraf
NO951447D0 (no) Organoaluminoksyprodukt, fremstilling og anvendelse
DK0991666T3 (da) Alfa-1-antitrypsin-præparat og fremgangsmåde til fremstilling heraf
DK0668392T3 (da) Tagmembran og fremgangsmåde til fremstilling deraf
NO974169D0 (no) Fremgangsmåte for tetra-azacykloalkan-fremstilling
DK0635004T3 (da) 4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
TR199600857A2 (tr) Nikotinamidin hazirlanmasi icin islem.
DK1003383T4 (da) Smagsforstærkende N-ethyl-p-menthan-3-carboxamidindeholdende forbindelser og fremgangsmåde til fremstilling og anvendelse deraf
DK0735042T3 (da) Maltitolsammensætning og fremgangsmåde til fremstilling deraf
DK0732276T3 (da) Spraydåse og fremgangsmåde til dens fremstilling
KR970702922A (ko) 독소루비신의 제조방법(Process for preparing doxorubicin)
NO970136D0 (no) Granulös formulering inneholder mikroorganismer, fremgangsmåte for fremstilling og anvendelse derav
NO960766D0 (no) Nytt protein og fremgangsmåte for fremstilling av dette
NO993863D0 (no) Forbindelser og fremgangsmåte for fremstilling av substituerte 4-fenyl-4-cyanocycloheksansyrer